![](/images/graphics-bg.png)
The efficacy of solifenacin added to α-adrenergic antagonists in the treatment of lower urinary tract symptoms in males with benign prostate hyperplasia : (the Iraqi experience)
المؤلفون المشاركون
al-Hamdani, Nibras I.
Daraji, Sad D.
Zaki, Ali W.
المصدر
Journal of the Faculty of Medicine Baghdad
العدد
المجلد 57، العدد 2 (30 يونيو/حزيران 2015)، ص ص. 119-124، 6ص.
الناشر
تاريخ النشر
2015-06-30
دولة النشر
العراق
عدد الصفحات
6
التخصصات الرئيسية
الموضوعات
الملخص EN
-Background : The response of overactive bladder (OAB) symptoms seen in men with Lower urinary tract symptoms / Benign prostate hyperplasia (LUTS/BPH) raises the possibility that a combination of α-adrenergic blocker therapy with anticholinergic therapy could both reduce the risk of retention or deteriorating bladder function and also add to the treatment of the remaining obstructive symptoms of LUTS / BPH.
Objective : Is to investigate the efficacy and tolerability of 5mg solifenacin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia in combination with an alpha-blocker.
Patients and methods : This is a prospective study of 29 patients with benign prostatic hyperplasia already on alpha-blockers, given solifenacin 5mg once daily.
International prostate symptom score (IPSS), patient micturition diaries, quality of life index (QOL), post-void residual urine (PVR) and maximum flow rate (Qmax) and urodynamic findings were recorded before and after three months of therapy.
Adverse events were documented.
Results: At baseline, the total IPSS was 15.3+5.7 that decreased to 10.8 + 5.3 (net change -4.5, P value < 0.03).
Although the mean IPSS for voiding symptoms was not significant, significant change was noted in the storage symptoms (from 8.4 + 2.4 to 5.1+ 2.5 P value <0.001).
The quality of life index was significantly improved for the patients enrolled from 4.4 + 1.4 to 2.8 + 1.3.
The maximum flow rate increased from 11.6 + 5.7 to 14.3 + 6.1 with a net change of + 2.7 ml / sec (P value < 0.01) ml/sec.
Two patients stopped the medication because of side effects.
The side effects included dry mouth (17.24 %) followed by constipation (6.90 %) then headache and blurred vision (3.45 %) for each.
No urine retention developed in any patient.
Conclusions: The use of solifenacin in selected cases in the treatment of LUTS in patients with BPH is highly effective addition to alpha-blockers
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
al-Hamdani, Nibras I.& Daraji, Sad D.& Zaki, Ali W.. 2015. The efficacy of solifenacin added to α-adrenergic antagonists in the treatment of lower urinary tract symptoms in males with benign prostate hyperplasia : (the Iraqi experience). Journal of the Faculty of Medicine Baghdad،Vol. 57, no. 2, pp.119-124.
https://search.emarefa.net/detail/BIM-592736
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
al-Hamdani, Nibras I.…[et al.]. The efficacy of solifenacin added to α-adrenergic antagonists in the treatment of lower urinary tract symptoms in males with benign prostate hyperplasia : (the Iraqi experience). Journal of the Faculty of Medicine Baghdad Vol. 57, no. 2 (2015), pp.119-124.
https://search.emarefa.net/detail/BIM-592736
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
al-Hamdani, Nibras I.& Daraji, Sad D.& Zaki, Ali W.. The efficacy of solifenacin added to α-adrenergic antagonists in the treatment of lower urinary tract symptoms in males with benign prostate hyperplasia : (the Iraqi experience). Journal of the Faculty of Medicine Baghdad. 2015. Vol. 57, no. 2, pp.119-124.
https://search.emarefa.net/detail/BIM-592736
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 123-124
رقم السجل
BIM-592736
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)